CGM Catches Hidden Blood Sugar Problems After Kidney Transplant

What Was Studied and Why It Matters

Kidney transplants are life-changing procedures — but they come with a serious hidden risk. Up to 1 in 4 kidney transplant recipients develops a new form of diabetes after surgery, called post-transplant diabetes mellitus (PTDM). This condition raises the chances of heart problems, organ rejection, and even early death.

Researchers from BMC Nephrology reviewed the latest evidence on whether continuous glucose monitors (CGMs) — small wearable sensors that track blood sugar around the clock — could do a better job than traditional blood tests at spotting and preventing these problems in kidney transplant patients.

What the Research Found

The results were striking. Here's what the evidence showed:

• CGMs caught problems that standard tests missed. The traditional HbA1c test — which gives a 3-month average of blood sugar — performed poorly in the weeks right after transplant. It frequently misclassified patients as having normal blood sugar when they actually had dangerous spikes and swings throughout the day.
• CGM predicted future diabetes with high accuracy. Using CGM data from the first month after surgery, researchers could predict who would go on to develop PTDM with a sensitivity above 85% and specificity up to 83%. That means doctors could intervene much earlier.
• Blood sugar variability is a key danger signal. Kidney-only transplant recipients showed higher blood sugar swings than recipients of other organs. Patients with existing type 2 diabetes also had more variability than those who developed PTDM after transplant.
• Poor early glucose control predicted organ rejection. High glucose variability in the first weeks after surgery was linked to acute rejection and reduced long-term graft survival — making early detection critically important.
• CGM helped doctors adjust medications more precisely. When CGM data guided adjustments to immunosuppressants (anti-rejection drugs) and steroids — both of which raise blood sugar — patients experienced less hyperglycemia overall.

What This Means for Real Patients

If you or a loved one is preparing for a kidney transplant, this research has practical takeaways. The drugs needed to prevent organ rejection are known to spike blood sugar, and the first few weeks after surgery are a critical window. Wearing a CGM during this period could give your care team a complete, real-time picture of what your blood sugar is doing — not just a single snapshot from a finger-prick test.

Despite this strong evidence, CGMs are not yet a standard part of transplant care protocols. That may be changing as awareness grows. For people already managing diabetes who also face transplant, having reliable CGM supplies on hand is more important than ever. MDS Diabetes carries a full range of CGM sensors and diabetes management supplies to help you stay prepared through every stage of care.

Bottom Line

A continuous glucose monitor can detect dangerous blood sugar patterns in kidney transplant recipients far earlier and more accurately than traditional tests. This early warning can help prevent new-onset diabetes, reduce the risk of organ rejection, and guide smarter medication adjustments. If you or someone you care for is facing a kidney transplant, ask your transplant team about CGM monitoring — the data could make a meaningful difference in long-term outcomes.